FTC to increase Section 5 scrutiny over ‘Orange Book’ abuses

Pharmaceutical companies that improperly list patents in the Food and Drug Administration’s Orange Book could be in breach of rules that prevent unfair methods of competition, the Federal Trade Commission has said.

Unlock unlimited access to all Global Competition Review content